Ivan Lopez-ibor | Médico

• Pharmacological and Neuromodulatory Strategies Following SSRI Non-Response in Major Depressive Disorder: Divergent U.S. and European Treatment Pathways and the Emerging Role of Novel FDA-Approved Interventions

  Ivan Lopez-ibor
  06/05/2026
  

  I. López-Ibor, MD Clínica López-Ibor, Madrid, Spain. Sanatorio del Dr Esquerdo, Madrid, Spain. Clinica del Dr Leon, Madrid, Spain. South Florida Integrative Medicine, Miami, Florida. Correspondence: drivanlopezibor@gmail.com Abstract Selective serotonin reuptake inhibitors (SSRIs) remain the cornerstone of first-line pharmacotherapy for major depressive disorder (MDD); however, remission following an initial adequate SSRI trial remains limited in routine clinical practice. When...

    ENLACE
• Pharmacological and Neuromodulatory Strategies Following SSRI Non-Response in Major Depressive Disorder: Divergent U.S. and European Treatment Pathways and the Emerging Role of Novel FDA-Approved Interventions

  Ivan Lopez-ibor
  06/05/2026
  

  I. López-Ibor, MD Clínica López-Ibor, Madrid, Spain. Sanatorio del Dr Esquerdo, Madrid, Spain. Clinica del Dr Leon, Madrid, Spain. South Florida Integrative Medicine, Miami, Florida. Correspondence: drivanlopezibor@gmail.com Abstract Selective serotonin reuptake inhibitors (SSRIs) remain the cornerstone of first-line pharmacotherapy for major depressive disorder (MDD); however, remission following an initial adequate SSRI trial remains limited in routine clinical...

    ENLACE
• SSRI Treatment Failure: Contemporary Mechanisms, Diagnostic Pitfalls, and Evidence-Based Next Steps (2021–2025 Update)

  Ivan Lopez-ibor
  05/05/2026
  

  I. López-Ibor, MD ABSTRACT Selective serotonin reuptake inhibitors (SSRIs) remain first-line pharmacological treatment for major depressive disorder (MDD). However, real-world remission rates remain modest, and “treatment failure” is frequently misclassified (1). Contemporary evidence highlights that non-response is often driven by diagnostic error, inadequate dosing/duration, pharmacokinetic variability, or comorbid psychiatric conditions rather than true pharmacological...

    ENLACE

Comentarios publicados

• No has hecho comentarios